BA PHARMA
ActiveSummary
The computed 12-month bankruptcy probability of BA PHARMA is 1.6% (moderate). The 2025 annual accounts show equity of €146,387 and a net result of €689. Equity is growing by about 14% per year across the filed financial years. Its solvency ranks better than 18% of 12,678 sector peers (NACE 47, financial year 2025). The company has been active since 2018 and the Belgian Official Gazette contains no insolvency or warning signals.
Group and network
Holdings and subsidiaries
1 holdingHoldings 1
- NEUPHARMAsubsidiarySourceact 11-10-2023100%
Sources: the companies' annual accounts, the acts in the Belgian Official Gazette and the LEI register. Annual accounts state the shareholders that notified the company under article 7:225 of the Code of Companies and Associations and the parent companies that consolidate it. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not include these statements in its annual accounts, or does not have to, is not listed.
Connections & network
1 current directorThe network starts from this company’s directors. Other companies they run appear here as nodes.